Highlights on Genetic Polymorphism Associated with Thromboembolic Risk; Implications in Ophthalmic and Autoimmune Disorders—A Review

The present paper explores genetic polymorphism and its association with thromboembolic retinal venous disorders, such as central/hemi-retinal vein occlusion, as well as possible correlations with other ocular findings, such as closed angle glaucoma, but also with autoimmune general disorders. In this review, we are highlighting the importance of establishing a correspondence between all of the above, since they all have complex etiopathogeneses; sometimes, when all coexist together, they could generate effects that may be very difficult to manage. There are studies supporting that genetic polymorphism, such as the variant MTHFR A1298C, may increase the risk for developing glaucoma, especially in the heterozygote model. Being aware of all these aspects may prove to be useful in patients with several associated diseases, as a combined effort between several medical specialties may prove to the benefit of these patients. Our review, completed with an exemplifying clinical case, shows that it is necessary to raise awareness of all aspects of a complex medical situation, including the genetic one, of a patient being at risk for thromboembolic episodes, for preventing them or managing them promptly and properly in the future.

[1]  Anália do Carmo,et al.  Thrombophilic risk factors for retinal vein occlusion , 2019, Scientific Reports.

[2]  P. Lu,et al.  Association of glaucoma with risk of retinal vein occlusion: A meta‐analysis , 2019, Acta ophthalmologica.

[3]  S. G. Çevik,et al.  Effects of Common Thrombophilia Factor Mutations in Central Retinal Vein Occlusion , 2019, Beyoglu eye journal.

[4]  H. Neamatzadeh,et al.  Association of MTHFR C677T and A1298C Polymorphisms with Glaucoma Risk: a Systematic Review Meta-Analysis based 42 Case-Control Studies , 2019, Romanian journal of ophthalmology.

[5]  Lingling Wu,et al.  Primary angle closure and primary angle closure glaucoma in retinal vein occlusion , 2018, Acta ophthalmologica.

[6]  K. Bućan,et al.  Genetic Background of a Recurrent Unusual Combined Form of Retinal Vein Occlusion: A Case Report , 2018, Case Reports in Ophthalmology.

[7]  S. Pouria,et al.  Is Central Retinal Vein Occlusion (CRVO) due to hereditary ischemia risk factors , 2018 .

[8]  Tyler B. Johnson,et al.  Methylenetetrahydrofolate Reductase A1298C Polymorphism and Major Depressive Disorder , 2017, Cureus.

[9]  M. Lee,et al.  Health care claims for primary open-angle glaucoma and retinal vein occlusion from an 11-year nationwide dataset , 2017, Scientific Reports.

[10]  Tin Aung,et al.  Inter-eye comparison of retinal oximetry and vessel caliber between eyes with asymmetrical glaucoma severity in different glaucoma subtypes , 2016, Clinical ophthalmology.

[11]  R. Zarei,et al.  COMPARISON OF ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY PARAMETERS BETWEEN CENTRAL RETINAL VEIN OCCLUSION AND NORMAL EYES: Is Primary Angle Closure a Risk Factor for Central Retinal Vein Occlusion? , 2015, Retina.

[12]  G. Damante,et al.  Thrombophilic Mutations as Risk Factor for Retinal Vein Occlusion , 2015, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[13]  D. Friedman,et al.  Retinal Vessels Change in Primary Angle-Closure Glaucoma: The Handan Eye Study , 2015, Scientific Reports.

[14]  A. Bellatorre,et al.  Homocysteine , MTHFR C 677 T gene polymorphism , folic acid and vitamin B 12 in patients with retinal vein occlusion , 2015 .

[15]  Q. Nguyen,et al.  Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics , 2014, Pharmacogenomics and personalized medicine.

[16]  Yazhou He,et al.  Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis. , 2014, Thrombosis research.

[17]  P. Kolar Risk Factors for Central and Branch Retinal Vein Occlusion: A Meta-Analysis of Published Clinical Data , 2014, Journal of ophthalmology.

[18]  S. Schneeweiss,et al.  Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis , 2013, Arthritis care & research.

[19]  A. Gialeraki,et al.  Retinal vein occlusion: genetic predisposition and systemic risk factors , 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[20]  J. Jonas,et al.  PREVALENCE AND ASSOCIATIONS OF RETINAL VEIN OCCLUSIONS: The Central India Eye and Medical Study , 2013, Retina.

[21]  Javier Martín,et al.  Genetic Markers of Cardiovascular Disease in Rheumatoid Arthritis , 2012, Mediators of inflammation.

[22]  L. M. Srivastava,et al.  Higher incidence of C677T polymorphism of the MTHFR gene in North Indian patients with vascular disease , 2012, Vascular.

[23]  B. Illades-Aguiar,et al.  PAI-1 mRNA expression and plasma level in rheumatoid arthritis: relationship with 4G/5G PAI-1 polymorphism , 2012, Rheumatology International.

[24]  Mustafa R. Kadhim,et al.  Homocysteine in the Pathogenesis of Chronic Glaucoma , 2011 .

[25]  T. Kubena The Mystery of Glaucoma , 2011 .

[26]  Andrea Sodi,et al.  Retinal vein occlusions: a review for the internist , 2011, Internal and emergency medicine.

[27]  K. Park,et al.  Retinal nerve fiber layer thickness is decreased in the fellow eyes of patients with unilateral retinal vein occlusion. , 2011, Ophthalmology.

[28]  Hua Yang,et al.  Prevalence of glaucoma in North China: the Beijing Eye Study. , 2010, American journal of ophthalmology.

[29]  P. Foster,et al.  Retinal Vein Occlusion and Angle Closure: A Retrospective Case Series , 2010, Journal of glaucoma.

[30]  P. Bernstein,et al.  Demographic characteristics, patterns and risk factors for retinal vein occlusion in Nepal: a hospital‐based case–control study , 2010, Clinical & experimental ophthalmology.

[31]  Javier Llorca,et al.  A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis , 2010, Arthritis research & therapy.

[32]  M. Kass,et al.  The incidence of retinal vein occlusion in the ocular hypertension treatment study. , 2010, Ophthalmology.

[33]  C. Pournaras,et al.  Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. , 2009, Ophthalmology.

[34]  S. Bonovas,et al.  The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. , 2008, Thrombosis research.

[35]  Mingguang He,et al.  Prevalence and clinical characteristics of glaucoma in adult Chinese: a population-based study in Liwan District, Guangzhou. , 2006, Investigative ophthalmology & visual science.

[36]  N. Goldenberg,et al.  Associations of Thrombophilia, Hypofibrinolysis, and Retinal Vein Occlusion , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[37]  A. Bellatorre,et al.  Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12 in patients with retinal vein occlusion , 2005, Thrombosis journal.

[38]  S. Hayreh Prevalent misconceptions about acute retinal vascular occlusive disorders , 2005, Progress in Retinal and Eye Research.

[39]  A. Gori,et al.  Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels , 2004, Thrombosis and Haemostasis.

[40]  W. T. Shults,et al.  Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease , 2004, British Journal of Ophthalmology.

[41]  S. Hayreh,et al.  Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. , 2004, Ophthalmology.

[42]  J. Geleijnse,et al.  4G/4G Genotype of PAI-1 Gene Is Associated With Reduced Risk of Stroke in Elderly , 2003, Stroke.

[43]  T. Bombeli,et al.  Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems , 2002, American journal of hematology.

[44]  M. Sanak,et al.  Mutation A1298C of methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. , 2001, American journal of medical genetics.

[45]  J H Eckfeldt,et al.  The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. , 2001, Atherosclerosis.

[46]  C. Krakau,et al.  Arguments for a vascular glaucoma etiology , 1993, Acta ophthalmologica.

[47]  FRCP W. J. MacLennan MD,et al.  The Elderly , 1984, Treatment in Clinical Medicine.

[48]  T. Bertelsen THE RELATIONSHIP BETWEEN THROMBOSIS IN THE RETINAL VEINS AND PRIMARY GLAUCOMA , 1961, Acta ophthalmologica.